ArticleTherapeutic advances in hematology2026
The impact of chemotherapy relative dose intensity on survival in elderly patients with extranodal NK/T-cell lymphoma: A retrospective cohort study.
Article in Therapeutic advances in hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Optimizing chemotherapy for elderly patients with extranodal natural killer/T-cell lymphoma (ENKTL) represents a significant clinical challenge, requiring a balance between effective relative dose intensity (RDI) and treatment tolerance. The prognostic impact of RDI in this population remains unclear. Objectives: To investigate the relationship between RDI and survival outcomes and to establish a clinically meaningful RDI threshold for elderly ENKTL patients. Design: A retrospective observational single-center cohort study. Methods: The study analyzed treatment-naïve ENKTL patients aged ≥60 years who received DDGP-like regimens or P-GEMOX regimen between May 2016 and December 2023. The optimal RDI cutoff was determined by receiver operating characteristic curve analysis. Variable selection for multivariable Cox regression was performed using least absolute shrinkage and selection operator (LASSO) regression to mitigate overfitting and adjust for potential confounders. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Results: A total of 79 patients were enrolled. The median number of chemotherapy cycles was 3 (IQR: 3-5), with a median treatment interval of 26 days (IQR: 23-31). Treatment delays exceeding one week occurred in 55.7% of patients (n = 44), and only 2.5% (n = 2) received full dose intensity (RDI = 1). An average RDI ≥ 0.62 was significantly associated with prolonged PFS ( Conclusion: An ARDI ≥ 0.62 may represent a critical threshold associated with improved prognosis in elderly ENKTL. However, this observation is preliminary and warrants further validation in prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.